On January 30, Intellectual Property counsel Janet Linn will serve as a panelist at the 2020 New York State Bar Association’s Food, Drug & Cosmetic Law Section Meeting.

Janet will be a featured speaker at the meeting’s Drug and Biologics Update, which will examine patent invalidating agreements and overbroad claims (Helsinn v. Teva; Idenix v. Gilead); the possibility of the U.S. Supreme Court making a decision in relation to invalidity under Section 101; claiming natural ingredients (National Alternatives v. Creative Compounds) and method of treatment/dose adjustment (Hikma v. Vanda and Endo v. Teva); recent case precedent impacting the FTC's ability to obtain monetary remedies (FTC v. Shire ViroPharma, Inc.); and state and federal policy trends regarding biologics/biosimilars as well as pertinent litigation.

This panel discussion will provide 2.0 CLE credits in the Professional Practice category. Learn more and register.